Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Jaypirca“
Suchtreffer
Begriffe & Kennungen
Jaypirca
Eintrag öffnenJaypirca · 4.1 Therapeutic indications · 1
Eintrag öffnenJaypirca · 4.3 Contraindications · 1
Eintrag öffnenJaypirca · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenJaypirca · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenJaypirca · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenJaypirca · 4.5 · 5 P-gp substrates Pirtobrutinib is a weak inhibitor of P-gp. Pirtobrutinib increased the AUC and Cmax of digox
Eintrag öffnenJaypirca · 4.5 · BCRP substrates Pirtobrutinib is a moderate inhibitor of BCRP. Pirtobrutinib increased the AUC and Cmax of ros
Eintrag öffnenJaypirca · 4.5 · CYP2C19 substrates Pirtobrutinib is a weak inhibitor of CYP2C19. Pirtobrutinib increased the AUC and Cmax of o
Eintrag öffnenJaypirca · 4.5 · CYP2C8 substrates Pirtobrutinib is a moderate inhibitor of CYP2C8. Pirtobrutinib increased the AUC and Cmax of
Eintrag öffnenJaypirca · 4.5 · CYP3A inducers In a clinical study, rifampin, a strong CYP3A inducer, decreased the AUC and Cmax of pirtobruti
Eintrag öffnenJaypirca · 4.5 · CYP3A inhibitors In a clinical study, itraconazole, a strong CYP3A4 inhibitor, increased the AUC of pirtobruti
Eintrag öffnenJaypirca · 4.5 · CYP3A substrates Pirtobrutinib is a weak inhibitor of CYP3A. Pirtobrutinib increased the AUC and Cmax of orall
Eintrag öffnenJaypirca · 4.5 · Effects of other medicinal products on the pharmacokinetics of pirtobrutinib
Eintrag öffnenJaypirca · 4.5 · Effects of pirtobrutinib on the pharmacokinetics of other medicinal products (increase in plasma concentration
Eintrag öffnenJaypirca · 4.5 · Pirtobrutinib is primarily metabolised by CYP3A4, UGT1A8, and UGT1A9.
Eintrag öffnenJaypirca · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenJaypirca · 4.8 Undesirable effects · 1
Eintrag öffnenJaypirca · 4.8 · 7 Epistaxis Common (4.2) 0.1 Haematuria Common (4.8) 0.2 Haematoma Common (2.4) 0.3 Conjunctival Common (1.5)
Eintrag öffnenJaypirca · 4.8 · Fatal adverse reactions have been observed in 0.7 % of patients for pneumonia, in 0.3 % of patients for haemor
Eintrag öffnen